Intravitreal bevacizumab for refractory diabetic macular edema

Retina-Vitreus

Volumn 20, Issue 4, 2012, Pages 265-272

  Yilmaz, Melike Balikoǧlu ^a   Teke, Mehmet Yasin ^a   Saritepe, Seher ^a   Kara, Caner ^a   Taşkintuna, Ibrahim ^a   Öztürk, Faruk ^a  

^a SB Ankara Ulucanlar Eye Education and Research Hospital   (Turkey)

Author keywords

Diabetic macular edema; Intravitreal bevacizumab; Vascular endothelial growth factor

Indexed keywords

ANTIGLAUCOMA AGENT; BEVACIZUMAB; CEFTAZIDIME; TRIAMCINOLONE; VANCOMYCIN;

ABRASION; ADULT; AGED; ARTICLE; CONJUNCTIVAL HEMORRHAGE; CORNEA INJURY; DIABETIC MACULAR EDEMA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHACOEMULSIFICATION; PROSPECTIVE STUDY; REFRACTORY DIABETIC MACULAR EDEMA; RETINA FOVEA; RETINAL THICKNESS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VISUAL ACUITY; VITRECTOMY;

EID: 84872090512     PISSN: 13001256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Nicholson BP, Schachat AP. A review of clinical trials of anti- VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-30.
2. Hussain F, Arif M, Ahmad M. The prevalence of diabetic retinopathy in Faisalabad, Pakistan: a population-based study. Turk J Med Sci 2011;41:735-42.
3. Richter B, Kohner E. Medical interventions for diabetic retinopathy. In: Wormald R, Smeeth L, Henshaw K, eds. Evidence- Based Ophthalmology. London: BMJ Books 2004:331-40.
4. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-61.
5. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:15-27.
6. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
7. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006;113:294-301.
8. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-57.
9. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-50.
10. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmol 2006;113:1706-12.
11. Nyugen QD, Shah SM, Khwaja A, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ- 2) study. Ophthalmology 2010;117:2146-51.
12. Kaiser PK: Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660-68.
13. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25.
14. Early Treatment Diabetic Retinopathy Study research group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
15. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30:287-290.
16. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamsinolon versus bevacizumab for treatment of refractory diabetic macular oedema . Br J Ophthalmol 2008;92;76-80.
17. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
18. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-95.
19. Arevalo JF, SanchezJG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan- American Collaborative Retina Study Group at 24 months. Ophthalmology 2009;116:1488-97.
20. Schmid KE, Neumaier-Ammerer B, Stolba U, et al. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 2006;244:1446-52.
21. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-67.
22. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86.
23. Soheilian M, Garfami KH, Ramezani A, et al. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 2012;32:314-21.
24. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
25. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelvemonth safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
26. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9.
27. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
28. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.
29. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007;85:119-20.
30. Chung EJ, Roh MI, Kwon OW, et al. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008;28:957-63.
31. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina 2006;26:1006-13.
32. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-8.
33. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for highrisk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385-9.
34. Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-2.
35. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-81.
36. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9.
37. Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 2008;28:1314-8.
38. Salam A, DaCosta J, Sivaprasad S. Anti-vascular endothelial growth factor agents for diabetic maculopathy. Br J Ophthalmol 2010;94:821-6.